Boehringer Ingelheim suspends early study for pill candidate after ‘safety event’

News Business Boehringer Ingelheim suspends early study for pill candidate after ‘safety event’ August 24, 2026 | 1 min read | Tristan Manalac Twitter LinkedIn Facebook Email Print Not much is known about Boehringer Ingelheim’s drug candidate, dubbed BI 3031185, though the asset has completed at least two other Phase 1 studies this year. Boehringer Ingelheim has put a Phase 1 study for an investigational oral drug on ice after detecting a safety event.The suspension was revealed in a U.S. clinical trials database, as per an Aug.

19 update to the study page, though the trial is being run in Japan. A spokesperson confirmed the pause to BioSpace via email on Monday morning but declined to provide additional details.“Patient safety is central to Boehringer Ingelheim. Enrolment in the study is currently on a voluntary hold while a safety event is being evaluated,” the spokesperson said.

“The assessment is ongoing, and we will provide an update once an outcome is known.”The German pharma is testing the oral drug candidate, named BI 3031185, as a possible treatment for certain mental health conditions, starting with a Phase 1 study of healthy adults. One part of the trial is assessing the tolerability of the drug in men, while another was looking at its effects on the concentration of a contraceptive in the blood of women. None of the study’s sites are in the U.S.

Not much is known about BI 3031185. The molecule this year completed two other Phase 1 studies: one looking at how it interacts antifungal drug itraconazole—as sold by Johnson & Johnson as Sporanox—and another involving patients diagnosed with borderline personality disorder or attention-deficit/hyperactivity disorder.The pharma’s latest pipeline document doesn’t list the molecule names for early-stage assets, though there are three Phase 1 programs for “mental health.” One is a glutamate receptor modulator, another is an acetyltransferase inhibitor, and the third is tagged simply as a “receptor agonist.” MASH Boehringer Ingelheim Axes MASH Pact With OSE After Disappointing Mid-Stage Data OSE Immunotherapeutics has kicked off a strategic realignment initiative that involves deprioritizing the AbbVie-partnered OSE-230 and focusing its resources on the late-stage development of its ulcerative colitis candidate lusvertikimab. March 3, 2026 · 2 min read · Tristan Manalac Read more Zooming out on other recent pipeline activities, the pharma has continued to be an active dealmaker, signing with Boston’s Sitryx Therapeutics just days before the OSE exit.

For up to $500 million in payments, plus royalties, Boehringer gained access to a small-molecule program for a variety of autoimmune and inflammatory conditions. In January, the pharma also put up to $1.26 billion on the line to partner with China’s Simcere Pharmaceutical for inflammatory bowel disease treatments. Twitter LinkedIn Facebook Email Print Pipeline Phase 1 Boehringer Ingelheim Tristan Manalac Tristan is BioSpace‘s senior staff writer.

Based in Metro Manila, Tristan has more than eight years of experience writing about medicine, biotech and science. He can be reached at tristan.manalac@biospace.com, tristan@tristanmanalac.com or on LinkedIn.